Study of plasma level of atorvastatin and its effect on lipid profile

Indian Journal of Physiology and Pharmacology

Volumn 53, Issue 1, 2009, Pages 73-82

  Valera, Heema R ^a,c   Ganguly, Barna ^b  

^a Institute of Science and Technology for Advanced Studies and Research   (India)

^b Pramukh Swami Medical College   (India)

^c NONE

Author keywords

Atorvastatin; HDL C; Hyperlipidemia; Lipid profile; Plasma level

Indexed keywords

ATORVASTATIN; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; AREA UNDER THE CURVE; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG EFFICACY; FEMALE; HUMAN; HYPERLIPIDEMIA; INDIA; LIPID BLOOD LEVEL; MALE; MAXIMUM PLASMA CONCENTRATION; POPULATION RESEARCH; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; ANTICHOLESTEREMIC AGENTS; CHOLESTEROL; COHORT STUDIES; FEMALE; HEPTANOIC ACIDS; HUMANS; HYPERLIPIDEMIAS; MALE; PYRROLES; TIME FACTORS; TRIGLYCERIDES;

EID: 70349381105     PISSN: 00195499     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Enas EA, Mehta JL. Malignant Coronary Artery Disease in young Asian Indians. Thoughts on Pathogenesis, prevention and therapy. N Engl J Med 1995; 333: 1301-1307.
2. Heller R. For INCLEN Multicentre Collaborative Group. Risk factors for cardiovascular disease in the developing world. A multicentre collaborative study in the International Clinical Epidemiology Network (INCLEN). J Clin Epidemiol 1992; 45: 841-847.
3. Enas EA, Yusuf S, Mehta JL. Prevalence of Coronary Artery Disease in Asian Indians - Editorial. Am J Cardiol 1992; 70: 945-949.
4. Herfindal ET, Gourley DR. Textbook of Therapeutics. Drug and Disease management, Seventh edition: 407-427.
5. Dipro TJ, Talbert RL, Yee GC, Natzke GR, Wells BG, Posey LM, Pharmacotherapy - A pathophysiologic Approach, Sixth edition, Mc Graw Hill, Medical Publishing Division: 429-452.
6. Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4,444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 334: 1383-1389.
7. Tall AR. Plasma high-density lipoprotein. Metabolism and relationship to atherogenesis. J Clin Invest 1990; 86: 379-384.
8. Shek A, Ferrill MJ. Statin-fibrate combination therapy. Ann Pharmacother 2001; 35: 908-917.
9. Whitfield LR, Stern RH, Sedman AJ, Abel R, Gibson DM. Effect of food on the pharmacodynamics and pharmacokinetics of atorvastatin, an inhibitor of HMG-CoA reductase. Eur J Drug Metab Pharmacokinet 2000; 25(2): 97-101.
10. Course JR, Kastelein J, Isaacsohn J, et al. A large, 36 week study of the HDL-C raising effects and safety of Simvastatin versus atorvastatin. Atherosclerosis 2000; 151: 8-9.
11. Jones P, Kafonek S, Laurora I, Hunninghake D. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin and fluvastatin in patients with hypercholesterolemia (the CURVES study). Am J Cardiol 1998; 81: 582-587.
12. Pedersen TR, Tobert JA. Benefits and risks of HMG-CoA reductase inhibitors in the prevention of coronary heart disease. A Reappraisal Drug Saf 1996; 14: 11-24.
13. Stern RH, Yang BB, Hounslow NJ, et al., Pharmacokinetics and pharmacodynamic relationships of atorvastatin, an HMG-CoA reductase inhibitor. J Clin Pharmacol 2000; 40: 616-623.
14. von Eckardstein A, Assmann G. Prevention of coronary heart disease by raising high-density lipoprotein cholesterol? Curr Opin Lipidol 2001; 11: 627-637.
15. Roeters van Lennep JE, Westerveld HT, Roeters van Lennep HWO, et al. Apolipoprotein concentrations during treatment and recurrent coronary artery disease events. Arterioscler Thromb Vasc Biol 2000; 20: 2408-2413.
16. Crouse JR III, Frohlich J, Ose L, et al. Effects of high doses of simvastatin and atorvastatin on high-density lipoprotein cholesterol and apolipoprotein A-I. Am J Cardiol 1999; 83: 1476-1477.
17. Kastelein JJP, Isaacsohn JL, Ose L, et al. Comparison of effects of simvastatin versus atorvastatin on high-density lipoprotein cholesterol and apolipoprotein A-I levels. Am J Cardiol 2000; 86: 221-223.
18. Illingworth DR, Grouse JR III, Hunninghake DB, et al. A comparison of simvastatin and atorvastatin up to maximal recommended doses in a large multicenter randomized clinical trial. Curr Med Res Opin 2001; 17: 43-50.
19. Ma P, Hegele RA, Yale JF, et al. CAVEAT: a randomized, double-blind, parallel group evaluation of cerivastatin 0.4 mg and 0.8 mg compared to atorvastatin 10 mg and 20 mg once daily in patients with combined (type IIb) dyslipidemia. Br J Cardiol 2000; 7: 780-786.
20. Wierzbicki AS, Lumb PJ, Semra Y, et al. Atorvastatin compared with simvastatin-based therapies in the management of severe familial hyperlipidemias. QJM 1999; 92: 387-394.
21. Wierzbicki AS, Lumb PJ, Chik G, et al. High-density lipoprotein cholesterol and triglyceride response with simvastatin versus atorvastatin in familial hypercholesterolemia. Am J Cardiol 2000; 86: 547-549, A9.
22. Davidson M, Ma P, Stein EA, et al. {Comparison of effects on low-density lipoprotein cholesterol and high-density lipoprotein cholesterol with rosuvastatin versus atorvastatin in patients with type Ha or lib hypercholesterolemia. Am J Cardiol 2002; 89: 268-275.
23. Sposito A.C, Gonbert S, Bruckert E, et al. Magnitude of HDL Cholesterol Variation After High-Dose Atorvastatin Is Genetically Determined at the LDL Receptor Locus in Patients With Homozygous Familial Hypercholesterolemia. Arteriosclerosis, Thrombosis, and Vascular Biology 2003; 23: 2078.
24. Lipitor® (atorvastatin calcium): Prescribing Information; http://www.pfizer.com/files/products/uspi_lipitor.pdf